PNC Financial Services Group’s LAVA Therapeutics LVTX Stock Holding History

PNC Financial Services Group’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-65,000	Closed	-$101K	–	5254
2025 Q3	$101K	Hold	65,000	–	–	﹤0.01%	2797
2025 Q2	$85.8K	Hold	65,000	–	–	﹤0.01%	2813
2025 Q1	$82.5K	Hold	65,000	–	–	﹤0.01%	2794
2024 Q4	$61.8K	Hold	65,000	–	–	﹤0.01%	2968
2024 Q3	$108K	Hold	65,000	–	–	﹤0.01%	2625
2024 Q2	$117K	Hold	65,000	–	–	﹤0.01%	2529
2024 Q1	$216K	Hold	65,000	–	–	﹤0.01%	2119
2023 Q4	$103K	Hold	65,000	–	–	﹤0.01%	2589
2023 Q3	$95.5K	Hold	65,000	–	–	﹤0.01%	2595
2023 Q2	$132K	Buy	65,000 +15,000	+30%	+$27.7K	﹤0.01%	2471
2023 Q1	$83K	Hold	50,000	–	–	﹤0.01%	2687
2022 Q4	$175K	Buy	+50,000	New	+$229K	﹤0.01%	2214

PNC Financial Services Group's LVTX Position: Q4 2025 in Review

PNC Financial Services Group sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 65,000 shares — an estimated $101K sold.

PNC Financial Services Group first reported a position in LVTX in Q4 2022 and held it in 12 quarters. The position peaked at $216K in Q1 2024. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.

PNC Financial Services Group reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
PNC Financial Services Group sold 65,000 LAVA Therapeutics shares in Q4 2025, an estimated $101K.
PNC Financial Services Group first reported a position in LAVA Therapeutics in Q4 2022 and held it in 12 quarters.
PNC Financial Services Group's LAVA Therapeutics position peaked at $216K in Q1 2024.
0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.

Based on PNC Financial Services Group's 13F filing for Q4 2025, filed 6 Feb 2026.